Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2020 Filed May 29, 2020 10:48 UTC |
Basenese LouDirector
|
PurchaseCommon Stock | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0001209191-20-032826 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,068 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $0.92, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 27, 2020 Filed May 28, 2020 10:47 UTC |
Basenese LouDirector
|
PurchaseCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001209191-20-032502 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 26, 2020 Filed May 27, 2020 11:25 UTC |
Basenese LouDirector
|
PurchaseCommon Stock | 10,000 | $0.82 | $8,200.00 |
DisclosureSEC source: 0001209191-20-032219 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 22, 2020 Filed May 26, 2020 11:03 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001209191-20-031895 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,083 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.74 to $0.81, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| May 21, 2020 Filed May 22, 2020 10:17 UTC |
Basenese LouDirector
|
PurchaseCommon Stock | 10,000 | $0.71 | $7,100.00 |
DisclosureSEC source: 0001209191-20-031547 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,068 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:42 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024215 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,083 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:35 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
GrantCommon Stock | 123,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024209 · doc4.xml · nonDerivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,561 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:39 UTC |
Wells David R.Chief Financial Officer
|
GrantCommon Stock | 79,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024213 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,653 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:46 UTC |
Tokman Alexander YDirector
|
GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024217 · doc4.xml · nonDerivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,857 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 16:50 UTC |
Gambhir Sanjiv SamDirector
|
GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024218 · doc4.xml · nonDerivative · entry 1 Gambhir Sanjiv Sam · CIK 0001369005 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,857 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:45 UTC |
Harsh MichaelDirector
|
GrantCommon Stock | 42,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024216 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,857 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:40 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
GrantCommon Stock | 86,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024214 · doc4.xml · nonDerivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,580 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 20:37 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantCommon Stock | 96,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024211 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,963 F1 · shares: Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| April 09, 2020 Filed Apr 15, 2020 20:41 UTC |
Basenese LouDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-20-024484 · doc4.xml · derivative · entry 2 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-09 F3 · shares: Represents a stock option award granted on April 9, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. F4 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning April 9, 2021. Read SEC document |
| April 09, 2020 Filed Apr 15, 2020 20:41 UTC |
Basenese LouDirector
|
GrantCommon Stock | 41,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024484 · doc4.xml · nonDerivative · entry 1 Basenese Lou · CIK 0001809482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,587 F1 · shares: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 22:02 UTC |
Wells David R.Chief Financial Officer
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-20-005185 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 25, 2021. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 22:03 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001209191-20-005187 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning January 25, 2021. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:19 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001778 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:23 UTC |
Tokman Alexander YDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001805 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:21 UTC |
Gambhir Sanjiv SamDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001787 · doc4.xml · derivative · entry 1 Gambhir Sanjiv Sam · CIK 0001369005 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:22 UTC |
Harsh MichaelDirector
|
GrantStock Options · Derivative | 12,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-20-001796 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantWarrants · Derivative | 100,503 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · derivative · entry 3 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,503 Underlying: Common Stock · 100,503 shares Expires 2024-12-11 F2 · price: The Warrants were issued for no additional consideration in connection with the purchase of the common stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock option (right to buy) · Derivative | 89,585 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 89,585 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:48 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantCommon Stock | 100,503 | $0.87 | $87,437.61 |
DisclosureSEC source: 0001209191-19-060084 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,226 Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:51 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
GrantWarrants · Derivative | 5,026 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 3 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,026 Underlying: Common Stock · 5,026 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:51 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
GrantSeries A Convertible Preferred Stock · Derivative | 4.372 | $1,143.68 Strike: $0.87 | $5,000.17 |
DisclosureSEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 2 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4.372 Underlying: Common Stock · 5,026 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:51 UTC |
Michelon Francois RogerDirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 611,994 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060089 · doc4.xml · derivative · entry 1 Michelon Francois Roger · CIK 0001691470 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,994 Underlying: Common Stock · 611,994 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC |
Wells David R.Chief Financial Officer
|
GrantWarrants · Derivative | 10,051 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 3 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,051 Underlying: Common Stock · 10,051 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC |
Wells David R.Chief Financial Officer
|
GrantSeries A Convertible Preferred Stock · Derivative | 8.744 | $1,143.68 Strike: $0.87 | $10,000.34 |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8.744 Underlying: Common Stock · 10,051 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:54 UTC |
Wells David R.Chief Financial Officer
|
GrantStock option (right to buy) · Derivative | 138,375 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060093 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,375 Underlying: Common Stock · 138,375 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:48 UTC |
Gambhir Sanjiv SamDirector
|
GrantStock option (right to buy) · Derivative | 89,585 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060086 · doc4.xml · derivative · entry 1 Gambhir Sanjiv Sam · CIK 0001369005 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 89,585 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 17:53 UTC |
Tokman Alexander YDirector
|
GrantStock option (right to buy) · Derivative | 89,585 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060092 · doc4.xml · derivative · entry 1 Tokman Alexander Y · CIK 0001334483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,585 Underlying: Common Stock · 89,585 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:52 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantWarrants · Derivative | 50,252 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060091 · doc4.xml · derivative · entry 3 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,252 Underlying: Common Stock · 50,252 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:52 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantSeries A Convertible Preferred Stock · Derivative | 43.719 | $1,143.68 Strike: $0.87 | $50,000.55 |
DisclosureSEC source: 0001209191-19-060091 · doc4.xml · derivative · entry 2 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43.719 Underlying: Common Stock · 50,252 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:52 UTC |
Thornton Michael MilosChief Technology Officer
|
GrantStock option (right to buy) · Derivative | 575,906 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060091 · doc4.xml · derivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,906 Underlying: Common Stock · 575,906 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:50 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
GrantStock option (right to buy) · Derivative | 42,859 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060088 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,859 Underlying: Common Stock · 42,859 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC |
Harsh MichaelDirector
|
GrantWarrants · Derivative | 11,056 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 3 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,056 Underlying: Common Stock · 11,056 shares Expires 2024-12-11 F4 · price: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC |
Harsh MichaelDirector
|
GrantSeries A Convertible Preferred Stock · Derivative | 9.618 | $1,143.68 Strike: $0.87 | $10,999.91 |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9.618 Underlying: Common Stock · 11,056 shares Expires not disclosed F2 · derivative.exercise_price: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87. F3 · derivative.expiration_date: The Series A preferred stock has no expiration date. Read SEC document |
| December 11, 2019 Filed Dec 11, 2019 22:49 UTC |
Harsh MichaelDirector
|
GrantStock option (right to buy) · Derivative | 89,922 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-19-060087 · doc4.xml · derivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,922 Underlying: Common Stock · 89,922 shares Expires 2029-12-11 F1 · derivative.exercise_date: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date. Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 20:16 UTC |
Wells David R.Chief Financial Officer
|
PurchaseCommon Stock | 10,000 | $1.18 | $11,800.00 |
DisclosureSEC source: 0001209191-19-051091 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 20:18 UTC |
Wells David R.Chief Financial Officer
|
PurchaseCommon Stock | 5,000 | $1.55 | $7,750.00 |
DisclosureSEC source: 0001209191-19-047405 · doc4.xml · nonDerivative · entry 2 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.59, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 20:18 UTC |
Wells David R.Chief Financial Officer
|
PurchaseCommon Stock | 5,000 | $1.56 | $7,800.00 |
DisclosureSEC source: 0001209191-19-047405 · doc4.xml · nonDerivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 10, 2019 Filed Jun 14, 2019 21:39 UTC |
Harsh MichaelDirector
|
PurchaseCommon Stock | 500 | $1.14 | $570.00 |
DisclosureSEC source: 0001209191-19-037236 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:26 UTC |
Harsh MichaelDirector
|
PurchaseCommon Stock | 2,800 | $1.12 | $3,136.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 3 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:26 UTC |
Harsh MichaelDirector
|
PurchaseCommon Stock | 6,600 | $1.11 | $7,326.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 2 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.16, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 05, 2019 Filed Jun 10, 2019 20:26 UTC |
Harsh MichaelDirector
|
PurchaseCommon Stock | 100 | $1.20 | $120.00 |
DisclosureSEC source: 0001209191-19-035800 · doc4.xml · nonDerivative · entry 1 Harsh Michael · CIK 0001706155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| May 28, 2019 Filed May 30, 2019 23:33 UTC |
Maloberti Renaud BertrandChief Commercial Officer
|
GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-19-033525 · doc4.xml · derivative · entry 1 Maloberti Renaud Bertrand · CIK 0001744025 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 28, 2020. Read SEC document |
| May 16, 2019 Filed May 20, 2019 12:20 UTC |
Thornton Michael MilosChief Technology Officer
|
PurchaseCommon Stock | 30,000 | $1.13 | $33,900.00 |
DisclosureSEC source: 0001209191-19-031215 · doc4.xml · nonDerivative · entry 1 Thornton Michael Milos · CIK 0001706297 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.19, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:00 UTC |
Wells David R.Chief Financial Officer
|
GrantStock Options · Derivative | 56,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-19-030069 · doc4.xml · derivative · entry 1 Wells David R. · CIK 0001480371 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: These Stock Options become exercisable in three equal annual installments beginning on May 13, 2020. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:06 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock Options · Derivative | 50,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-19-021518 · doc4.xml · derivative · entry 2 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-25 F1 · shares: Represents a stock option award granted on March 25, 2019 pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: This stock option grant becomes exercisable in three equal annual installments beginning March 25, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.